Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026

Nuvectis Pharma (NVCT) will discuss third-quarter 2026 financial results and recent business progress on a conference call on November 4, 2026.

Rhea-AI Summary

Nuvectis Pharma (NVCT) will discuss third-quarter 2026 financial results and recent business progress on a conference call on November 4, 2026. The call and webcast will begin at 8:00 AM ET and cover the quarter ended September 30, 2026. The webcast will be available through the company's Investor Relations Events and Presentations page, with a replay archived for at least 30 days.

Key Terms

complement factor b inhibitor, pnh, braf inhibitor, src family kinases

4 terms

complement factor b inhibitor medical

"a complement Factor B inhibitor in development for the treatment of complement-mediated diseases"

A complement factor B inhibitor is a drug designed to block a specific protein (factor B) in the body’s immune “alarm” system, preventing that system from overreacting and damaging healthy tissue. For investors it signals a targeted therapy approach with potentially clear clinical trial milestones, market opportunity in certain immune-driven diseases, and regulatory and reimbursement risks tied to safety, efficacy and competition—much like backing a precision tool that could replace a blunt instrument in treatment.

pnh medical

"recently approved in China for the treatment of PNH patients"

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired bone‑marrow stem cell disorder in which a genetic change in blood‑forming cells makes red blood cells abnormally vulnerable to destruction by the complement system, a part of the immune system. That complement‑mediated breakdown of red cells causes episodes of dark or red urine, anemia, and a higher risk of blood clots and other complications; diagnosis rests on specialized blood tests that detect the abnormal cell population and treatment commonly targets the complement pathway to reduce hemolysis and related risks.

braf inhibitor medical

"an oral, brain-penetrant, paradox-breaker BRAF inhibitor"

A BRAF inhibitor is a type of drug that blocks the activity of the BRAF protein, which can drive uncontrolled cell growth when mutated in certain cancers. For investors, BRAF inhibitors matter because they are a targeted therapy class with regulatory pathways, clinical trial milestones, and market potential tied to specific tumor types and mutation tests; think of them as a precision switch that can stop a malfunctioning growth signal in tumors.

src family kinases medical

"a small molecule inhibitor of the SRC family kinases"

A group of closely related non-receptor tyrosine enzymes that add phosphate groups to tyrosine residues on proteins to control cell signaling. Src family kinases sit at the inner side of the cell membrane and help regulate processes such as cell growth, movement, adhesion and survival by turning signaling pathways on or off through phosphorylation; their activity is controlled by phosphorylation at specific sites and by interactions with other proteins. Because their switching changes how cells respond to external cues, abnormal activation or loss of control of these kinases is a common mechanism in diseases such as cancer and in some disorders of the immune and nervous systems.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026. 

Conference Call and Webcast Information:
Date: 8:00 AM ET, Wednesday, November 4, 2026
Participant Dial-In (U.S.): 1-877-407-0752
Participant Dial-In (International): 1-201-389-0912
Conference ID: 13763643
Webcast Access: Please click here

The live and archived webcast can also be accessed by visiting the Nuvectis Pharma website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP200 and NXP900, in development for the treatment of advanced cancers.

The company’s lead drug candidate is NXP100 (ciprocopan), a once-a-day Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors.

NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, with best-in-class potential.

NXP900 is an oral, small molecule inhibitor of the SRC family kinases, including SRC and YES1.

Company Contact:

Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com

Media Relations Contact:

Kevin Gardner
LifeSci Advisorskgardner@lifesciadvisors.com